
The National Institute of Allergy and Infectious Diseases has launchedĀ a clinical trial to evaluate a potential COVID-19 treatment regimen for hospitalized patients that combines remdesivir with interferon beta-1a, a medication approved to treat multiple sclerosis that laboratory studies suggest may benefit patients with COVID-19. T